$10B M&A Deal Pays Off With GSK’s First Lung Cancer Drug Approval
Frank Vinluan / medcitynews - GSK drug Jideytro received FDA approval for treating advanced cases of non-small cell lung cancer driven by ROS1 alterations. This molecule came from Nuvalent, which GSK recently acquired for $10.6 billion. The post $10B M&A Deal Pays Off With GSK’s First…
AI Summary: GSK has won FDA approval for its first lung cancer drug, a gene-targeting therapy that validates the company’s heavy investment and recent M&A strategy. The approval follows pivotal trial evidence of clinical benefit and positions GSK competitively in thoracic oncology, offering a new therapeutic choice for patients with the relevant molecular profile.
Related Stories
FDA clears pivekimab sunirine (Decnupaz) as first BPDCN ADC / 1 month
FDA to revisit Atara/Pierre Fabre cell therapy approval for rare lymphoma / 2 months
FDA advisory panel rejects camizestrant after SERENA‑6 results / 2 months
Ten‑year follow‑up shows durable remissions with CD19 CAR‑T therapy / 28 days
FDA greenlights datopotamab deruxtecan for metastatic TNBC / 28 days
FDA approves belzutifan (Welireg) plus pembrolizumab for adjuvant RCC / 5 wks
FDA clears first all-oral regimen for certain newly diagnosed AML patients / 7 wks
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pancreatic Cancer, Vitamin D, Gene Therapy, Mergers and Acquisitions and look for the RSS link.
StackHealth Time Machine